A cloud-based artificial intelligence system, named Caddie, has shown significant improvements in the detection of adenomas, including those that are hard to detect in the proximal colon. This was especially evident when used by non-expert endoscopists in the UK. The findings were presented at UEG week. Rawen Kader, MRCP, PhD, a clinical research fellow at University College London, emphasized that while many previous trials in this field were conducted by expert endoscopists, the main advantage of AI in polyp detection was hoped to benefit non-expert endoscopists. Key findings from the study include: Rawen Kader also highlighted that each increase in…
Author: Abhay Panchal
Optum’s data and analytics division experienced a 35% year-over-year revenue growth following its acquisition of Change Healthcare for $13 billion. This was highlighted in UnitedHealth Group’s third-quarter earnings report released on October 13th. The report also mentioned that the revenue backlog surged by over $7 billion, reaching a total of more than $31 billion compared to the previous year. The growth in revenue was attributed not only to the acquisition but also to the technology products and services from Optum Insight that are marketed to health systems, payers, and life sciences organizations. For the third quarter, Optum’s overall revenue stood…
COPENHAGEN, Denmark — A real-time, blood-sensing capsule (PillSense, EnteraSense Ltd) that detects upper gastrointestinal bleeding (UGIB) is safe and effective for patients before undergoing upper endoscopy, according to results from the first US open-label, single-arm comparative clinical trial of a novel bleeding sensor for patients with suspected UGIB. It is also the largest such trial. This tool is rapidly deployed, safe to use, and easy to interpret, study researchers say. In under 7 minutes, the capsule correctly detected the presence of blood in 26 of 28 patients and its absence in 87 of 96 patients, as confirmed afterward by esophagogastroduodenoscopy…
CHICAGO—On average, surgeons are much less likely than gastroenterologists to detect adenomas during routine screening colonoscopy, according to a VA data set. Based on the lower relative adenoma detection rate (ADR), the disparity “highlights potential opportunities for quality improvement,” according to study investigator Andrew J. Gawron, MD, PhD, a gastroenterologist at the VA Salt Lake City Health Care System and an assistant professor at the University of Utah, also in Salt Lake City. The study analyzed 669,434 colonoscopies performed by 1,095 unique providers between October 2018 and September 2022. Although gastroenterologists greatly outnumbered surgeons (906 vs. 189) and performed 88.8%…
Debulking, when combined with standard systemic therapy, did not have a significant negative effect on the overall quality of life in patients with metastatic colorectal cancer. This was revealed in a study published in the Journal of the National Comprehensive Cancer Network. However, the study also found that patients who underwent the debulking procedure experienced serious adverse events at a rate twice as high as those who received standard treatment. Study Details: Future Implications: Bakkerus emphasized the need for further exploration, given the significant complications from local treatment without a noticeable dip in patients’ perceived quality of life. She suggested…
TOPLINE: People aged 75 years or older (the upper age limit of colorectal cancer [CRC] screening) who had a negative fecal immunochemical test (FIT) but a detectable fecal hemoglobin (f-Hb) concentration at their last screening are nearly five times as likely to develop CRC than are those with no detectable f-Hb concentration, suggests a study from the Netherlands. METHODOLOGY:
A cloud-based artificial intelligence system named Caddie has shown significant improvement in the detection of adenomas, especially the hard-to-detect lesions in the proximal colon. This was observed when used by non-expert endoscopists in the UK. The findings were presented at UEG week. Rawen Kader, MRCP, PhD, a clinical research fellow at University College London, emphasized that while most previous trials in this field were conducted by expert endoscopists, the main advantage of AI polyp detection was expected to benefit non-expert endoscopists. Key findings from the study: Thought-Provoking Questions/Insights:
The chair of Harvard Medical School’s bioinformatics department, Isaac Kohane, M.D., Ph.D., highlighted that artificial intelligence (AI) is poised to make its most significant initial impact in the healthcare sector through billing and reimbursement. Here are the main points: AI in Healthcare: Contrary to popular belief that AI would first revolutionize diagnosis or data analysis, Kohane believes its primary influence will be in the financial aspects of healthcare, specifically billing and reimbursement. Billing and Reimbursement: AI’s deterministic and discrete data capabilities make it well-suited for managing these areas. Kohane predicts that many healthcare professionals currently working for insurance companies to…
NEW YORK – Laboratory services provider Stone Diagnostics will offer Fibronostics’ artificial intelligence-based liver disease test to physicians in the US, the companies announced on Tuesday. The Liverfast test uses artificial intelligence and 10 blood-based biomarkers to provide information about the degree of fibrosis, steatosis, and activity of a patient’s liver, the companies said in a statement. The strategic partnership “gives us the comprehensive, efficient, reproducible, and scalable laboratory operations platform required to meet increasing Liverfast demand and allows us to focus on the most important needs of our prescribers and their patients,” Brock Smith, Fibronostics general manager for the…
A new DNA test system, the Common Hereditary Cancers Panel by Invitae Corp., has been granted marketing authorization by the US Food and Drug Administration (FDA). This system evaluates an individual’s genetic predisposition for certain cancers and is the first of its kind to receive such authorization. Here are the main points: Test Overview: The test uses next-generation sequencing to assess germline human genomic DNA extracted from a single blood sample. The system detects substitutions, small insertion and deletion alterations, and copy number variants in a panel of 47 targeted genes. Validation: The test’s approval followed the FDA’s review of…